Table 1.
Participants’ characteristics at baseline.
| Parameter at baseline | Total population(N = 1673) | PNT (n = 1591) | PT < 75 (n = 31) | PT ≥ 75 (n = 51) | p value ‡ | ||||
|---|---|---|---|---|---|---|---|---|---|
| N | Mean (SD) or percentage | N | Mean (SD) or percentage | N | Mean (SD) or percentage | N | Mean (SD) or percentage | ||
| Demographic data | |||||||||
| Age (years) | 75.33 (4.42) | 75.26 (4.38) | 77.13 (5.36) | 76.43 (4.74) | 0.03 | ||||
| Sex (women) | 1085 | 64.85% | 1062 | 66.75% | 13 | 41.94% | 10 | 19.61% | < 0.0001 |
| Education level (N = 1638)* | 0.68 | ||||||||
| No diploma or primary school certificate | 369 | 22.53% | 355 | 22.80% | 4 | 12.90% | 10 | 20.00% | |
| Secondary education | 553 | 33.76% | 528 | 33.91% | 10 | 32.26% | 15 | 30.00% | |
| High school diploma | 242 | 14.77% | 230 | 14.77% | 4 | 12.90% | 8 | 16.00% | |
| University level | 474 | 28.94% | 444 | 28.52% | 13 | 41.94% | 17 | 34.00% | |
| Clinical data | |||||||||
| Arterial hypertension | 899 | 53.74% | 830 | 52.17% | 28 | 90.32% | 41 | 80.39% | < 0.0001 |
| Diabetes | 160 | 9.56% | 143 | 8.99% | 2 | 6.45% | 15 | 29.41% | 0.0001 |
| BMI (N = 1666)* | 26.11 (4.08) | 26.00 (4.06) | 27.40 (3.97) | 28.96 (3.48) | < 0.0001 | ||||
| Fried score > 0 (N = 1603)* | 738 | 46.04% | 694 | 45.45% | 17 | 56.67% | 27 | 58.70% | 0.10 |
| ApoE4 carriers (N = 1298)* | 299 | 23.04% | 286 | 23.18% | 5 | 20.83% | 8 | 20.00% | 0.87 |
| Composite cognitive score | 1673 | 0.00 (0.67) | 1591 | 0.00 (0.67) | 31 | 0.30 (0.56) | 51 | -0.12 (0.76) | 0.0185 |
| Physical activity (minutes per week) | 1651 | 422.50 (405.04) | 1571 | 426.49 (407.56) | 30 | 398.58 (396.46) | 50 | 311.30 (309.46) | 0.06 |
| Inclusion criteria | |||||||||
| Gait speed (m/s) | 1.09 (0.26) | 1.09 (0.26) | 1.09 (0.25) | 1.12 (0.26) | 0.63 | ||||
| Memory complaint | 1659 | 99.16% | 1578 | 99.18% | 30 | 96.77% | 51 | 100.00% | 0.28 |
| IADL < 8 | 184 | 11.00% | 176 | 11.06% | 2 | 6.45% | 6 | 11.76% | 0.78 |
| Imaging data | |||||||||
| Florbétapir-PET > 0 (N = 270)* | 103 | 38.15% | 97 | 37.89% | 3 | 42.86% | 3 | 42.86% | 1.00 |
| Intervention group | 0.68 | ||||||||
| Omega 3 supplementation + Multidomain intervention | 414 | 24.75% | 390 | 24.51% | 9 | 29.03% | 15 | 29.41% | |
| Omega 3 supplementation only | 419 | 25.04% | 399 | 25.08% | 10 | 32.26% | 10 | 19.61% | |
| Multidomain intervention + placebo | 420 | 25.10% | 400 | 25.14% | 8 | 25.81% | 12 | 23.53% | |
| Placebo only | 420 | 25.10% | 402 | 25.27% | 4 | 12.90% | 14 | 27.45% | |
*Number of subjects with available data.
‡Statistical tests are comparing the three groups PNT, PT < 75 and PT ≥ 75.
ApoE4: apolipoprotein E4; BMI: body mass index; PNT:participants not treated; PT < 75 :participants treated less than 75% of the study follow-up; PT ≥ 75: participants treated more than 75% of the study follow-up; PET positron emission tomography, SD standard deviation.
Significative values are written in bold text.